Document is current

Article History

Accepted: 10 March 2021

First Online: 7 April 2021

Declarations

:

: This work was funded in part by a sponsored research agreement with Juno Therapeutics, a wholly owned subsidiary of Bristol-Myers Squibb (Project Agreement No. 9). This study was also funded by Haematology Society of Australia and New Zealand and Fred Hutchinson Cancer Research Center.

: S.F. holds provisional patents filed on the use of CAR-T cell therapy for hematologic malignancies. C.J.T. receives research funding from Juno Therapeutics, Nektar Therapeutics, TCR2, and AstraZeneca; is a member of scientific advisory boards and has options in Precision Biosciences, Eureka Therapeutics, Caribou Biosciences, Myeloid Therapeutics, and ArsenalBio; serves on scientific advisory boards for T-CURX and Century Therapeutics; has served on ad hoc advisory boards for Nektar Therapeutics, Allogene, Kite/Gilead, Novartis, Humanigen, Aptevo, PACT Pharma, Amgen, and AstraZeneca; and is an inventor on patents licensed or optioned by Fred Hutch to Juno Therapeutics/BMS.

: Not applicable.

: Not applicable.

: Not applicable.

: Data from Fig. are available from BloodSpot (bloodspot.eu), a publicly accessible database of gene expression in AML and normal hematopoiesis. Data from Table were retrieved from a custom search of “(chimeric antigen receptor OR CAR) AND acute myeloid leukemia” on ClinicalTrials.gov.

: Not applicable.

: SF wrote the manuscript and conceived the structure. CJT conceived the structure and edited the manuscript.

Free to read: This content has been made available to all.